drugset / Trial / NCT01112787

A Study to Evaluate the Irritation Potential of Tazarotene Foam on Skin in Healthy Volunteers

NCT01112787

Phase 1 Completed 39 enrolled Stiefel, a GSK Company GlaxoSmithKline · collab
RandomizedParallel-groupTriple-blindBasic science

Summary

The purpose of this study is to evaluate the irritation level of tazarotene foam after 21 days of exposure on the skin of healthy volunteers.

Timeline

Start
2010-03-26
Primary completion
2010-04-26
Completion
2010-04-26

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sodium Laural Sulfate Unknown 0.5 % Topical
Subject Tazarotene Small molecule 0.1 % Topical

Indications